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Cytokine antagonists and their potential 
therapeutic use 
Reno Debets and Huub F.J. Savelkoul 
Unraveling the interactions between 
cytokines and cytokine receptors is 
of crucial importance to the design 
of specific cytokine antagonists. A
general finding in this respect is 
iiiustrated by studies in which mice 
that are made deficient in cytokine 
receptors, by gene targeting, are 
more-severely affected than antici- 
pated, possibly due to sharing of re- 
ceptor chains by different cytokine 
receptors (J. Peschon, Seattle). By 
contrast, ligand (cytokine)-deficient 
mice appear to be less affected than 
anticipated, which may be due to 
the redundancy of cytokines. Nature 
confirms these findings: the severe 
combined immunodeficiency (SCID) 
mutation and the hyper-igM syn- 
drome are consequences of inter- 
leukin 2 receptor (IL-2R) ",/-chain 
and CD40 ligand (L) deficiencies, 
respectively. 
The in vivo relevance of (soluble) 
cytokine receptors has also been 
illustrated by several viruses. Vac- 
cinia and cowpox viruses encode a 
protein in their open reading flame 
(ORF) that displays homology with 
soluble IL-1R type II and is able to 
bind IL-113. Furthermore, proteins 
that bind to tumor necrosis factor 
(TNF) and to CC chemokines have 
been identified in the ORF of pox 
viral strains (B. Widmer, Seattle) 
and cytomegaloviruses (K. Neote, 
Grotoa), respectively. 
Cytokine receptors 
The cytokine receptors can be 
grouped into sevecal families and 
subfamilies, as shown in Table 1. 
IL-1 and IL-1R 
The genes for human IL-1 a, IL-113 
and IL-1 receptor antagonist (ra), 
as well as for IL-1R type I and II, 
are all located on chromosome 2, 
suggesting that these factors are 
New and excitiag developments in 
the understanding of the interac- 
tion between cytokines and their 
receptors, and the clinical appli- 
cation of cytokine antagonists, u ere 
discussed at a recent meeting*. 
Here, Reno Debets and Huub 
Savelkoul revisit hi:. progress. 
expressed in a coordinated fashion 
following cell activation. Cross- 
linking experiments have excluded 
the possibility of IL-1R type II 
being a 13-type receptor molecule, 
like the IL-6 signal transducer 
gpl30 (J.E. Sims, Seattle). IL-1R 
ype I and II clearly differ in the 
length of their cytoplasmic do- 
mains, comprising 213 and 29 
amino acids, respectively. Indeed, 
the type II receptor is unable to 
transduce signals intracellularly 
after IL-1 binding. Moreover, IL-1 
responsiveness only requires a few 
type I receptor molecules per cell, 
and these are probably expressed 
by all somatic cells, which is in 
accordance with the highly pleio- 
tropic functions of IL-1. IL-lra and 
IL-113 have similar, but not ident- 
ical, three-dimensional structures 
(S.P. Eisenberg, Boulder). The bind- 
ing of IL-lra to one binding site on 
1L-1R type I competitively blocks 
the binding of IL-la and IL-113, but 
does not induce an IL-l-like signal. 
IL-1R type I displays two bindine; 
sites for iL-la and IL-113, one of 
which is similar to the binding site 
for [L-ira and the other differing 
in location depending on whether 
IL-I~ or IL-113 is being bound. The 
latter binding site is necessary for 
receptor activation and sig.~al trans- 
duction. Thus, receptor binding 
and activation are two physically 
separate vents. 
*The meeting 'Regulation of Cytokine 
Activity for Therapeutic Development: 
Control of Inflammation, Growth and 
Differentiation' was held in Washington 
DC, USA, 3--4 March 1994. 
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In contrast o IL-1R type I, the 
type 1I receptor shows only signifi- 
cant binding affinitv for iL-i13. 
Shedding of IL-1R type II from the 
cell surface sometimes occurs spon- 
taveously, but can also be induced 
in vitro. Moreover, shedding occurs 
quickly and probably involves pro- 
teolvsis. This shedding may represent 
a physiological attempt towards 
feedback signaling, since soluble 
(s)IL-1R type II acts as a specific 
antagonist of IL-113. Indeed, slL-1R 
type II binds IL-113 and prevents an 
IL-1 response via cell-surface-bound 
IL-1R type I. Furthermore, IL-1R 
type II is upregulated by the anti- 
inflammatory cytokine IL-4. Thus, 
since IL-1R type II appears to be 
predominantly expressed in the 
basal ayer of epithelia, the receptor 
may act as a barrier mechanism 
whereby locally produced IL-113 is 
neutralized. 
IL-9 and IL-gR 
IL-9 stimulates the proliferation 
of early erythroid progenitor cells 
and acts in synergy with suboptimal 
doses of IL-4 for the production of 
IgG and IgE by murine B cells (J-C. 
Renauld, Leuven). In IL-4knock- 
out mice, IL-9 expression is severely 
depressed. Moreover, IL-9 displays 
mast cell growth-enhancing activity 
and seems to be a potent regulator 
of mast cell effector molecules (e.g. 
IL-9 induces the production of pro- 
teases, IL-6 and upregulates the 
expression of the FceRI o~-chain). 
Furthermore, lymph nodes from 
patients with Hodgkin's and large- 
cell anaplastic lymphoma constitut- 
ively produce IL-9. The IL-9R, 
expressed on ~ctivated T cells, has 
a single high-affinity binding site 
(Ka=20pM) for IL-9. The extra- 
cellular part of the IL-gR is highly 
homologous to the IL-2R ~-chain, 
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Table 1. Cvtokine receptor families 
Families Ligands 
Class i ihematopoietic re eptors) 
common chain igp 130) 
13-chain 
~,-chain 
Class II I IFN receptors~ 
Ig superfamily receptors 
TNF-like receptors 
G-protein-coupled receptors 
IL-6, CNTF, OSM, LIF, IL-11 
IL-3, IL-5, GM-CSF 
IL-2, IL-4, IL-7, (IL-13, IL-15) 
IFN 
IL-1, CSF-1, Steel factor, FIt3L 
TNF, NGF, CD27L, CD30L, CD40L 
Chemokines 
Abbreviations: gp, glycoprotein, IU interleukin; CNq-F, ciliary neurotrophic factor; 
OSM, oncostatin M; LIF, leukemia inhibitory factor; GM-CSF, granulocyte-- 
macrophage colony-stimulating factor; IFN, interferon; Ig, immunoglobulin; 
CSF-I, colony-stimulating factor 1, FIt3U ligand of the fms-like tyrosine kinase; 
U ligand; ~F ,  tumor necrosis factor; NGF, nerve growth factor. 
and substantial homology has also 
been observed between the cyto- 
plasmic domains of the IL-9K and 
those of the IL-2R 13-chain and the 
receptor for eu'thropoietin (EPOR). 
IL- 1 ~ and IL- 15R 
A novel cDNA sequence has 
been isolated that corresponds to a 
15g.Da protein, termed IL-15, that 
displays IL-2-1ike functions but 
shares no significant s ructural hom- 
oloD; with IL-2 0.G. Giri, Seattle). 
It was found that the IL-15 mRNA 
is predominantly expressed in pla- 
centa and skeletal muscle tissue, 
and that IL-15 protein is produced 
by peripheral blood mononuclear 
cells {PBMCs), epithelial cells, fibro- 
blasts and endothelial cells, but not 
by activated peripheral T cells. This 
pattern of protein expression is 
complementary to that of IL-2. 
Furthermore, the IL-2- and IL-15- 
induced proliferation of PBMCs can 
be neutralized by antibodies against 
the IL-2R a- and 13-chain respect- 
ively. Binding studies with phyto- 
hemagglutinin (PHA)-stimulated 
PBMCs have shown that these cells 
display only one class of binding 
site for IL-15, but display two 
classes of binding sites for IL-2. In 
IL-2-knockout mice, T-cell functions 
are normal, possibly due to IL-15 
substituting for the deficient IL-2. 
However, in SCID mice, which lack 
the IL-2R ~/-chain, IL-15 cannot 
Table 2. Regulators of cytokine activity 
~'pe Possible mechanism ofaction 
Cytokine antagonists 
Non-peptidic molecules 
Soluble receptors 
IL- 1 ra/mutated cytokines 
Autoantibodies 
Cytokine agonists 
Soluble receptors/ 
autoantibodies 
Interfere with cytokine synthesis, receptor binding 
or signal transduction 
Scavenge, neutralize and prevent extravascular 
escape 
Prevent induction of receptor-mediated signal 
transduction 
Neutralize; nhance complcment-mediated 
killing of cells expressing membrane-bound 
or surface-receptor-bound cytokine 
Increase the persistence and chaperoning of 
cytokines 
Abbreviation: II -!ra, interleukin I receptor antagonist. 
substitute for the loss of IL-2 since it 
,~!so requires the ~/-chain for signal 
transduction. Triple-negative thymo- 
cytes express the IL-2R a-, 13- and 
~/-chains, and yet are unresponsive 
to IL-15, suggesting the existence 
of a separate IL-15-binding IL-15R 
a-chain. 
Regulation of cytokine activity 
Regulators of cytokine activity, 
displaying antagonistic as well as ag- 
onistic funct'ons, are summarized in
Table 2. Some of the antagonistic 
regulators may have therapeutic 
value. 
Non-peptidic antagonists 
Small, and preferably orally 
active, non-peptidic molecules are 
considered the ideal antagonists 
(G. Garotta, Basel). However, to 
date, the only effective antagonist 
has been isothiazolone A, which 
interferes with IL-5 binding to its 
receptor (R. De Vos, Gent). 
Soluble receptors 
Soluble cytokine receptors pro- 
vide a natural source of highly 
selective cytokine inhibitors. How- 
ever, apart from antagonizing 
cytokine activity, soluble receptors 
can also agonize cytokine activity, 
thereby acting as 'double-edged 
swords' (K.A. Clouse, Bethesda). 
Both these effects can result from 
the formation of complexes between 
the soluble receptor and its ligand, 
illustrating the carrier concept of 
soluble receptors. 
Soluble receptors, such as 
sTNFRs, are monomeric. These re- 
ceptors bind cytokine with less affin- 
ity than dimeric onstructs generated 
as a chimeric immunofusion protein 
with human IgG Fc, as has been 
carried out for TNFR type I (K. 
Mohler, Seattle). The sTNFR-Ig 
construct by itself does not activate 
complement and does not bind to 
FcR. This construct blocks the iipo- 
polysaccharide (LPS)-induced release 
of TNF-a in mice during the first 
2-3 hours after LPS injection and 
can prevent a lethal outcome. In an 
animal model of inflammatory lung 
disease, infection with Micropoly- 
spora faeni is known to induce the 
synthesis of TNF-c~ and IL-!cx, and 
this is antagonized by the sTNFR-Ig 
construct. When the M. faeni anti- 
gen was given intranasally at a dose 
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of 75~g during days 1-3, lung 
biopsies on days 4-7 showed infil- 
trates, primarily comprising neutro- 
phils, in the alveoli. Addition of 
sTNFR-Ig prevented the infiltrate 
to a significant extent. 
A slFN-~/R-Ig construct has been 
used in animal models of several 
diseases, including multiplc scler- 
osis (MS) and systemic lupus ery- 
thematosus (SLE) (G. Garotta). For 
example, NZB/W F ! mice spon- 
taneously develop an SLE-like syn- 
drome leading to mortality. The 
onset of kidney damage and mor- 
tality was significantly delayed by 
injection of slFN-~/R-Ig (1001a.g, 
three times weekly, for 18 weeks), 
and this treatment prevented sev- 
eral symptoms of disease, including: 
the onset of membrane-proliferative 
glomerulonephritis; the infiltration 
of T cells and macrophages into the 
kidney; the synthesis of IFN-~/and 
TNF-a; and the expression of major 
histocompatibility complex (MHC) 
class II, intercellular adhesion mol- 
ecule 1 (ICAM-1), vascular cell ad- 
hesion molecule 1 (VCAM-1) and 
IFN-~/R on the tubular epithelium 
and the glomerular cells. Treatment 
with this construct also delayed, but 
did not block, the appearance of 
autoantibodies to double-stranded 
(ds)DNA. Moreover, such therapy 
was not effective if mice already had 
proteinuria and severely elevated 
serum levels of autoantibodies to 
dsDNA. 
An animal model for acute 
bronchial eosinophilia was used to 
study the efficacy of either slL-5R 
a-chain or an immunofusion con- 
struct of this receptor (R. De Vos). 
Using IL-4-transgenic mice, sensi- 
tization with ovalbumin (OVA) 
caused increased levels of serum 
lgE. Challenge after two weeks 
with aerosols of OVA resulted in 
bronchial eosinophilic infiltrate and 
airway hyperresponsiveness. The 
eosinophilia could be inhibited effec- 
tively using either the slL-5R a-chain 
or the immunofusion construct. 
A clear demonstration of the 
'double-edged sword' phenomenon 
of cytokine receptors was presented 
by the murine slL-4R (C.R. 
Maliszewski, Seattle). On the one 
hand, sIL-4R antagonizes IL-4 ac- 
tivity in models of murine ailoreac- 
tivity (e.g. heart allograft survival) 
as well as models of anti-IgD 
immunization (e.g. inhibition of 
IgE production). On the other 
hand, complexes of slL-aR and 
IL-4 superinduce IgE responses dur- 
ing anti-IgD immunization. Further- 
more, sIL-4R-transgenic mice ex- 
pressing high levels of sIL-4R (e.g. 
in excess of 3 ~gml -~) displayed 
prolonged allograft survival. How- 
ever, these mice also showed a nor- 
mal antigen-specific IgE response 
by B cells, suggesting that even 
3 Ixg ml-! of sIL-4R does not block 
the IL-4-induced synthesis of IgE. 
The re _, between slL-4R and IL-4 
is crucml in determining the thera- 
peutic usefulness of slL-4R. The 
predominance of sIL-4R probably 
results in a shift away from a T 
helper 2 (Th2) response, which 
is beneficial in the treatment of 
Th2-dominant disease situations 
such as allergy, asthma, parasitic in- 
fections and AIDS. However, com- 
plexes with II-4 are likely to result 
in a shift towards Th2, which is 
useful in the treatment of Thl- 
dominant helminth and mycobac- 
terial infections. 
IL-lra 
Endogenous IL-lra regulates the 
pathophysiological effects of IL-1 
during acute inflammation (S.P. 
Eisenberg). In an acute model of 
immune colitis in rabbits, the kin- 
etics of changes in iL-la levels was 
synchronous with the time course 
of inflammation, whereas changes 
in IL-lra levels were delayed but 
prolonged when compared with the 
time course of inflammation. In 
normal colon tissue, IL-lra but not 
IL-la was detectable, and the maxi- 
mum IL-lra level during inflam- 
mation was approximately tenfold 
higher than the maximum IL-la 
level. The use of anti-IL-lra anti- 
body exacerbated inflammation, in- 
creased IL-la bioactivity and 
lowered the survival rate. IL-lra 
increased the survival of rabbits 
and rats in endotoxin-induced 
shock. Although IL-1 ra alone is less 
effective in severe models of shock, 
synergism is exhibited with sTNFR 
type I with respect o increasing the 
survival rate. 
Mutated cytokines 
A mutant form of IL-4, in which 
the tyrosine residue at amino acid 
position 124 is replaced by aspartic 
acid (YI24D), displays a three- 
dimensional structure similar to 
that of wild-type IL-4 (T. Mueller, 
Heidelberg). This mutant specifi- 
cally blocked IL-4- and IL-13- 
induced B-cell proliferation, as well 
as IgG4 and IgE synthesis, when cells 
were co-stimulated with anti-CD40 
monoclonai antibody (mAb)(G. 
Aversa, Palo Alto). Thus, IL-4 mu- 
tants may be useful as IL-4 antag- 
onists in the treatment of atopy. 
Analogs of granuiocyte-macrophage 
colony-stimulating factor (GM-CSF), 
in which the glutamic acid residue 
at position 21 is replaced by argi- 
nine or lysine, are defective at bind- 
ing to the [3-chain of GM-CSFR, 
and antagonize GM~CSF activity 
(J. Bagley, Adelaide). 
Anticytokine autoantibodies 
Recently; it was found that natu- 
ral autoantibodies to cytokines oc- 
cur under physiological conditions 
(K. Bendtzen, Copenhagen). Anti- 
cytokine autoantibodies are known 
to block bioactivity of the relevant 
cytokines, and can be found in the 
serum for IL-la, IL-6, IFN-a and 
IL-10. These antibodies are most 
often of the IgG1 or IgG4 isotype 
and all show affinities in the pM 
range. Furthermore, some serum 
antibodies bind aspecifically tocyto- 
kines (e.g. E'.-,:FJ,. IL-2, IL-4 and 
I L -~ J .  /~uroanr lDOOles  i~.,~xte iqot  L___  
found against IL-II3, IL-lra~ i;_2, 
IFN-13 or IFN-7. 
The 'double-edged sword' para- 
digm of soluble receptors also ap- 
plies to anticytokine autoantibodies. 
Small complexes between such 
antibodies and cytokines are unable 
to activate complement if IgG4 
antibodies are involved, and do not 
precipitate in vivo, but are active 
as inflammatory complexes. For 
these reasons, the therapeutic use 
of intravenous Ig preparations, dis- 
playing binding capacities for IL-la 
and IL-6, should be conskiered 
carefully. 
Conclusion 
Findings presented at this meet- 
ing clearly demonstrate the thera- 
peutic potential of cytokine antagon- 
ists. Non-peptidic antagonists (e.g. 
isothiazolone A), soluble cytokine 
receptors (e.g. sTNFR, slFN-~/R and 
slL-5R), the IL-lra and mutated 
cytokines (e.g. IL--I and GM-CSF) 
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may all be clinically useful, as dem- 
onstrated by transgenic and targeted 
mice, as well as animal models of 
disease and human diseases. How- 
ever, for therapeutic purposes, one 
should consider the possible agon- 
izing effects of soluble receptors 
and anticytokine autoantibodies 
(e.g. anti-IL-l~ autoantibody) on 
cytokine activity. 
It was not possible to include all of 
the interesting presentations given at the 
meeting in this brief report• We thank 
our colleagues for their critical reading 
of this paper. 
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Mucosal vaccines: high-tech reagents for 
low-tech immunization 
Claude E Muller 
Mucosal vaccines have a number of 
obvious advantages over invasive 
vaccines, particularly with respect 
to simplicity, safety and cost-effec- 
tiveness. Mucosal vaccines also 
provide a vehicle with which to tar- 
get antigens directly to the largest 
lymphoid organ systems - those 
associated with the gut and the res- 
piratory tract. In these organs, an 
effective local immune response 
may be required since they usually 
either constitute the route of entry 
of the pathogen or are prime 
targets of pathogen virulence. In 
some diseases, uch as peptic ulcers, 
the bacterial agent (Helicobacter 
pylori) and mechanisms of host 
immunity are only now unfolding 
{S. Abrignani, Siena). 
During Shigella flexneri infec- 
tions, an immune response iselicited 
against lipopolysaccharide (LPS) 
and invasins. The relative contri- 
burton of the s~tciaic and local 
response to immune protection 
following natural or experimental 
infection with S. flexneri is not 
fully understood. However, it is 
now reported that IgA mediates a
protective role against LPS (A. 
Phalipon, Paris). Attenuatea live 
mutants of S. flexneri have been 
developed by genetic inactivation 
Antigens are usually poorly im- 
munogenic when administered 
orally or intranasally and a variety 
of approaches have been designed 
to overcome this problem. Re- 
cently, the progress of six projects 
involving 24 laboratories funded 
by the 'Human and Veterinary 
Vaccines' section of the EC- 
Biotechnology programme were 
discussed at a meeting in 
Luxembourg ~.
nf  v i rn lpnrP  t :a r rnre  c , , rh  ~c th,~ 
proteins that mediate uptake of 
essential nutrients or mediate bac- 
terial mobility. These mutants were 
efficient in protecting monkeys 
against homologous virulent strainsL 
In addition, such nonvirulent mu- 
tants may provide vaccine vectors 
for delivering heterologous antigens 
that have been inserted into highly 
immunoger.ic secretory proteins (A. 
Phalipon). 
A protective role of early IgA 
has also been suggested for 
Toxoplasma goadii infection, fol- 
lowing the detection of specific 
secretory IgA molecules in human 
whey that were shown to neutralize 
the parasite in vitro. However, 
mouse monoclonal IgA antibodies 
directed against some of the major 
surface antigens of the tachyzoite 
*The First European Laboratory 
Without Walls (ELWW) meeting on 
"Mu, o,~al Immunity' was held in 
Luxembourg on 1-3 February 1994. 
© 1994, Elsevier Science Ltd 0167-5699/94/507.00 
(P30 or SAG1) have not yet been 
shown to be protective in vivo. 
Chronic parasite persistence with- 
out significant complications could 
be exploited therapeutically b using 
T. gondii as a convenient carrier of 
heterologous proteins. The potent 
l t l t l l l l l~ l lK . l~ l~. l l /~ . l lb~ '  K.lll I.llK, Id~l l~ l~ ~91d l l -  
ules of li-,e Toxoplasma makes 
them an attractive vehicle to deliver 
secreted heterologous antigens 
(M-E Cesbron, Lille). Indeed, the 
recent development of methods to 
manipulate tachyzoites genetically 
has opened up the possibility of 
introducing heterologous epitopes. 
Synthetic vaccines and adjuvants 
While the protective role of the 
lgA response remains to be estab- 
lished in the systems described 
above, protective epitopes have 
already been defined at the level of 
short peptides in other systems. Cur- 
rent field studies with Schistosoma- 
infected patients suggest hat the 
IgA response to defined peptide 
analogues of the S. mansoni 
glutathione-S-transferase protein 
(Sm28GST) correlates with a re- 
duction of parasite fecundity. 
Monoclonal anti-IgA antibodies to 
such peptides were shown to 
reduce parasite fecundity by passive 
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